About Us
We are developing Protein-Based Regenerative Medicine for major human disease therapies. Our goal is to develop innovative protein drugs including transcription factor (TF) protein drugs that can treat major human diseases, with the ultimate aim of improving human health and enhancing human longevity.
We have pioneered a unique approach of protein-induced in vivo/in situ disease tissue reprogramming technology platform. This approach involves in vivo reprogramming disease or injured, or degenerated tissue cells into stem cells using different reprogramming transcription factor protein drugs. These in situ protein-induced stem cells can then be guided to differentiate into younger healthy tissue cells by the natural cues that present in the differentiating resident tissue environments.
Qurgen has devoted significant efforts to developing innovative medical treatments that address the challenges of the current stem cell based regenerative medicine for major human disease therapies, leveraging our pioneered technology platforms, which significantly accelerate bench-to-bed clinical translation of stem cells technology. Qurgen’s first novel anticancer transcription factor drug (SON-DP) has obtained FDA approval for a first-in-human Phase I clinical trial in the US.